An ALK p.I1171T mutation was identified after relapse on crizotinib.40 The patient was changed to ceritinib and achieved a partial tumor response of 2 months.39,40 After progression on ceritinib, the patient was commenced on low-dose chemotherapy (vinorelbine, methotrexate, and ketorolac),41 which resulted in a complete metabolic response on fluorodeoxyglucose PET scan, but with progressive calcification and no objective shrinkage on CT scan and magnetic resonance imaging. This evidence concerns the gene ALK and neoplasm.